Eric Simpson, M.D., says the new Atopic Dermatitis Registry presents a “unique opportunity” for the research community.

In a roundup of COVID-19 questions for the U.S. presidential candidates, Mark Slifka, Ph.D., suggests asking the candidates the following: “Based on other successful countries such as South Korea, Japan, or Australia that have each demonstrated effective control of Covid-19, which ‘best-practices’ approaches of theirs would you consider implementing here in the U.S.?”

OHSU Doernbecher researcher Brittany Vuylsteke, M.P.H., sews masks for the William Temple House.

First responders practiced rescuing people from the Portland Aerial Tram near OHSU on Sept. 27.

Proceeds from the Tualatin Elks Lodge Oktoberfest beer garden will benefit the OHSU Casey Eye Institute.

OHSU’s Portland mobile COVID testing site is moving from the Expo Center to the Oregon Convention Center.

Esther Choo, M.D., is one of 60 medical and research leaders who wrote Pfizer a letter urging the company to wait until at least November before seeking FDA approval of its COVID-19 vaccine candidate.

Mark Slifka, Ph.D., says “it makes sense that the FDA wants to keep on digging” into why two participants in the AstraZeneca COVID vaccine trial reported neurological illnesses, which has prompted the trial to pause in the U.S.

In a feature about a Seattle researcher’s efforts to include more Native Americans in COVID-19 research, Kelly Gonzales, Ph.D., M.P.H., says “data can be used as a weapon to further marginalize and harm communities of color."

While discussing her Journal of Substance Abuse Treatment study, which found three-quarters of patients hospitalized for substance abuse use more than one substance, Caroline King, M.P.H., says “This is important because we may need to offer additional support to patients using multiple drugs. If someone with opioid use disorder also uses alcohol or methamphetamines, we miss caring for the whole person by focusing only on their opioid use.”